公开(公告)号：US10233243B2

公开(公告)日：2019-03-19

申请号：US14400812

申请日：2013-05-13

Applicant: UCB Biopharma SPRL

Inventor： Helene Margaret Finney ,  Alastair David Griffiths Lawson ,  Stevan Graham Shaw ,  Bryan John Smith ,  Kerry Louise Tyson ,  Lara Kevorkian ,  Christoph Meier ,  Kaushik Sarkar ,  Paul Alan Atherfold

IPC: C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  C07K16/28 ,  G01N33/50 ,  G01N33/564 ,  G01N33/68 ,  A61K47/60 ,  A61K47/64 ,  C07K1/00 ,  A61K39/00

Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

公开(公告)号：US10160798B2

公开(公告)日：2018-12-25

申请号：US15143162

申请日：2016-04-29

Applicant: President and Fellows of Harvard College ,  UCB Biopharma SPRL

Inventor： Gökhan S. Hotamisligil ,  Mehmet F. Burak ,  Feyza Engin ,  Scott B. Widenmaier ,  Elisabeth Helen Roberts ,  Adrian Richard Moore ,  Carl Brendan Doyle ,  Ralph Adams ,  Karine Jeannine Madeleine Hervé ,  Shauna Mhairi Wales ,  Kerry Louise Tyson

IPC: C07K16/18 ,  A61K39/00

Abstract: This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.